Qualified Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enterprise AI for health systems; raised $125M Series B (NEA + Anthropic fund, March 2026); 500K+ users; AI agents covering ~7% of US hospital revenue; integrates with existing EHR systems
About
Qualified Health is an enterprise AI company building intelligent systems for large health systems and hospital networks. Founded to address the complexity of clinical and operational decision-making in healthcare, the company develops AI agents that assist clinicians, administrators, and care teams with data-intensive workflows. Its platform is designed to integrate with existing electronic health record systems and enterprise infrastructure, enabling health systems to deploy AI without replacing legacy technology.\n\nThe company targets enterprise health systems — specifically the largest hospital networks in the United States — with AI tools that span clinical decision support, administrative automation, and patient engagement. Qualified Health emphasizes safety, compliance, and interpretability in its models, which is critical for adoption in regulated healthcare settings. The platform is built to handle the scale and data sensitivity requirements of organizations managing hundreds of thousands of patients.\n\nQualified Health raised a $125M Series B led by NEA and backed by the Anthropic fund, signaling strong confidence from both traditional healthcare investors and AI-native institutional backers. The company has grown to 500,000+ users and its platform now touches approximately 7% of total US hospital revenue — a remarkable reach for a relatively young company. As of early 2026, Qualified Health is one of the best-capitalized enterprise health AI startups in the market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.